Literature DB >> 7117372

Nifedipine reduces adenine nucleotide breakdown in ischemic rat heart.

J W De Jong, E Harmsen, P P De Tombe, E Keijzer.   

Abstract

An ATP-sparing effect has been demonstrated for a number of calcium antagonists. Nifedipine probably has a similar action, but data supporting this view are limited. Therefore we decided to study the effect of nifedipine on high-energy phosphate (and carbohydrate) metabolism in the ischemic rat heart. Langendorff preparations were made ischemic for less than 15 min. The reduction in coronary flow was 60 or 70%. Apex displacement during ischemia, a measure of contractility, was comparable for nifedipine-treated and untreated hearts. Ischemia caused a considerable release of the AMP catabolites adenosine, inosine and (hypo)xanthine, and of lactate. Nifedipine (10-100 micrograms/l) prevented this in a dose-dependent way. The highest dose reduced the release of purines and lactate by 90% (P less than 0.01) and 60% (P less than 0.001), respectively. The drug acted in a similar way during reperfusion. Due to ischemia, the adenylate energy charge (ATP + 0.5 ADP)/(ATP + ADP + AMP), decreased 15% (P less than 0.001); nifedipine at a concentration of 100 micrograms/l prevented this decrease (P less than 0.05). We conclude that nifedipine exerts a beneficial effect on myocardial adenine nucleotide metabolism during ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7117372     DOI: 10.1016/0014-2999(82)90604-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Nifedipine and experimental cardioprotection.

Authors:  W G Nayler; J J Liu; S Panagiotopoulos
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Protection of human, rat, and guinea-pig atrial muscle by mioflazine, lidoflazine, and verapamil against the destructive effects of high concentrations of Ca2+.

Authors:  U Ravens; G S Liu; G Vandeplassche; M Borgers
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

3.  Relation between energy metabolism, glycolysis, noradrenaline release and duration of ischemia.

Authors:  A Cargnoni; C Ceconi; S Curello; M Benigno; J W de Jong; R Ferrari
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

4.  Captopril improves recovery of adenosine triphosphate during reperfusion of the ischemic isolated rat heart; a 31-phosphorus-nuclear magnetic resonance study.

Authors:  F D Rahusen; W H van Gilst; G T Robillard; K Dijkstra; C R Wildevuur
Journal:  Basic Res Cardiol       Date:  1988 Sep-Oct       Impact factor: 17.165

Review 5.  Myocardial stunning--are calcium antagonists useful?

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

6.  Myocardial infarction in rats: effects of metabolic and pharmacologic interventions.

Authors:  H G Zimmer; P A Martius; G Marschner
Journal:  Basic Res Cardiol       Date:  1989 May-Jun       Impact factor: 17.165

7.  Comparison of dihydropyridine and phenylalkylamine calcium antagonists in patients with coronary heart disease.

Authors:  G F Rettig; M Jakob; S Sen; A Heisel
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 8.  Basic mechanisms involved in the protection of the ischaemic myocardium. The role of calcium antagonists.

Authors:  W G Nayler
Journal:  Drugs       Date:  1991       Impact factor: 9.546

9.  The influence of calcium antagonists on the adenine nucleotide metabolism in the guinea-pig working heart during ischaemia and reperfusion.

Authors:  J G Hugtenburg; M J Mathy; N de Haan; J J Beckeringh; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

Review 10.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.